GlassScriptPhysician profile
Harpreet Kaur
NPI 1427214170
$763.55
in general payments reported to CMS, 2019-2025
15 companies · $15.43 in 2025
The $15.43 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $77.88 · 2021: $41.95 · 2022: $12.02 · 2023: $94.45 · 2024: $54.85 · 2025: $15.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $221.87 | 2019-2020 | |
| Insulet Corporation | $167.44 | 2019-2024 | Omnipod |
| Abbott Laboratories | $67.73 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $55.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.06 | 2019 | |
| Novo Nordisk INC | $44.95 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $41.95 | 2021 | |
| Lilly USA, LLC | $28.84 | 2019-2024 | Zepbound |
| Sequel Med Tech, LLC | $15.43 | 2025 | Twiist |
| Medtronic, INC. | $12.85 | 2023 | Minimed 780g |
| Corcept Therapeutics | $12.64 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.02 | 2022 | |
| Shire North American Group INC | $11.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.17 | 2020 | |
| Medtronic Minimed, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harpreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.